Avalo Therapeutics, Inc. (AVTX) Balance Sheet
As of 2026-06-30 (10-Q), Avalo Therapeutics, Inc. (AVTX) reported total assets of $490.8M, total liabilities of $42.1M and shareholders' equity of $448.7M, according to EquiReason's reading of its SEC filings. Cash and equivalents: $85.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AVTXAvalo Therapeutics, Inc.Follow AVTX — free
—
Price chart with a free account
- Market cap
- 371.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 21.2 | 5.1 | 2.5 | 10.6 | 3.6 | 18.9 | 54.6 | 13.2 | 7.4 | 134.5 | 15.9 | 85.4 | |
| Short-term investments | — | — | — | — | — | — | — | — | — | 0.0 | 82.5 | 314.9 | |
| Receivables | — | — | — | — | — | — | — | 0.0 | — | — | — | — | |
| Inventory | — | 0.0 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | |
| Current assets | 21.6 | 5.7 | 10.7 | 21.9 | 17.7 | 26.0 | 61.8 | 16.4 | 8.4 | 138.9 | 105.3 | 407.9 | |
| Total assets | 21.7 | 5.8 | 42.8 | 70.3 | 36.1 | 43.8 | 80.2 | 33.4 | 21.0 | 150.7 | 116.5 | 490.8 | |
| Current liabilities | 5.8 | 4.3 | 11.1 | 26.2 | 12.2 | 15.2 | 19.9 | 22.1 | 4.6 | 7.0 | 12.9 | 21.1 | |
| Long-term debt | 2.4 | 0.0 | 0.0 | 14.3 | — | 0.0 | 32.8 | 13.5 | 0.0 | — | — | — | |
| Short-term debt | 3.2 | 2.4 | 0.0 | 1.1 | — | — | — | — | — | — | — | — | |
| Total liabilities | 8.6 | 5.6 | 14.9 | 49.3 | 15.1 | 19.2 | 57.1 | 44.3 | 13.7 | 17.7 | 33.4 | 42.1 | |
| Shareholders' equity | 13.1 | 0.2 | 27.9 | 20.9 | 21.0 | 24.6 | 23.1 | -10.9 | 7.3 | 133.0 | 83.0 | 448.7 |
USD millions · SEC XBRL
Avalo Therapeutics, Inc. — questions
- How much cash does Avalo Therapeutics, Inc. have?
- $85.4M in cash and cash equivalents as of 2026-06-30.
- What are Avalo Therapeutics, Inc.'s total assets?
- $490.8M as of 2026-06-30.
- What is Avalo Therapeutics, Inc.'s shareholders' equity?
- $448.7M as of 2026-06-30.
Every figure on this page comes from Avalo Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.